Phase 4
Completed N=42
Nebivolol and the Endothelin (ET)-1 System
Source: ClinicalTrials.gov NCT01395329 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: Systolic Blood Pressure — 144; 126; 140; 125 mmHg
◆ Published Evidence
Established
23citations · ~2 / year
Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure.
Summary
The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo.
Linked Publications
-
Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Systolic Blood Pressure |
144; 126; 140; 125; 139; 134 | — |
| PRIMARY Diastolic Blood Pressure |
89; 77; 90; 77; 86; 83 | — |
| PRIMARY Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min) |
10.2; -1.0; 10.0; 11.1; 13.1; 15.7 | — |
| PRIMARY Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min) |
10.2; -1.0; 10.0; 11.1; 13.1; 15.7 | — |
| PRIMARY FBF Response to Acetylcholine (ACh) |
5.2; 4.9; 5.3; 5.6; 4.8; 5.1 | — |
| PRIMARY FBF Response to Sodium Nitroprusside |
5.2; 4.7; 4.9; 5.7; 5.2; 5.2 | — |
| PRIMARY FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788) |
5.0; 4.7; 5.5; 6.0; 4.9; 5.1 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.
- Subjects will be prehypertensive/hypertensive defined as resting systolic blood pressure >130 mmHg and 80 mmHg and 126 mg/dL.
- Potential candidates with a resting heart rate of < 50 beats/minute will be excluded.
- Use of hormone replacement therapy.
- In hypertensive subjects, a seated systolic blood pressure greater than 160 mmHg or a seated diastolic blood pressure greater than 100 mmHg.
Data sourced from ClinicalTrials.gov (NCT01395329) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.